11 suspended. 11 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Suspended 11 |
| Phase 2 | 4 | Suspended 4 |
Follow Carcinoma, Bronchogenic: new trials by email Literature Review of Carcinoma, Bronchogenic trials Research Report on Carcinoma, Bronchogenic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin - Extensive-stage Small-cell Lung Cancer | Phase 1 | Suspended | University of Maryland, Baltimore | 50 | 2027-01-30 | 2026-09-14 |
| Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803 - Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 30 | 2026-11-01 | 2026-10-27 |
| Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) azacytidine, carboplatin, paclitaxel - Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 60 | 2026-11-01 | 2026-10-27 |
| Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer Atezolizumab, Biospecimen Collection, Computed Tomography - Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Suspended | Dwight Owen | 24 | 2024-12-31 | 2026-09-18 |
| Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO) Pembrolizumab, Difluoromethylornithine - Non Small Cell Lung Cancer, Lung Cancer | Phase 1 / Phase 2 | Suspended | H. Lee Moffitt Cancer Center and Research Institute | 45 | 2024-08-07 | 2026-03-06 |
| A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7 NPX267 - Metastatic Malignant Neoplasm | Phase 1 | Suspended | NextPoint Therapeutics, Inc. | 131 | 2023-07-21 | 2025-06-27 |
| A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 ChAdOx1-MAGEA3-NYESO (Route = IM injection, Dose = 5×10^10 vp), MVA-MAGEA3 (Route = IM injection, Dose = 1.3×10^8 pfu), Standard of care treatment - Non-small Cell Lung Cancer (NSCLC), Squamous Oesophageal Cancer | Phase 1 / Phase 2 | Suspended | Cancer Research UK | 15 | 2021-10-15 | 2026-04-06 |
| JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations JSI-1187, Dabrafenib - Solid Tumors | Phase 1 | Suspended | JS InnoPharm, LLC | 71 | 2020-06-18 | 2025-09-03 |
| A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2 - Solid Tumor | Phase 1 | Suspended | PACT Pharma, Inc. | 21 | 2019-07-03 | 2022-08-18 |
| A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC AMG 119 - Small Cell Lung Cancer | Phase 1 | Suspended | Amgen | 6 | 2018-09-10 | 2025-10-15 |
| A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies HGS1036 + Paclitaxel + Carboplatin, HGS1036 + Cisplatin + Etoposide, HGS1036 + Docetaxel - Cancer | Phase 1 | Suspended | Human Genome Sciences Inc., a GSK Company | 54 | 2012-06-01 | 2012-11-01 |
Carcinoma, Non-Small-Cell Lung (8) · Lung Neoplasms (5) · Neoplasms (3) · Prostatic Neoplasms (3) · Small Cell Lung Carcinoma (3) · Carcinoma, Transitional Cell (2) · Colorectal Neoplasms (2) · Melanoma (2) · Triple Negative Breast Neoplasms (2) · Carcinoma (1) · Carcinoma, Renal Cell (1) · Cholangiocarcinoma (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Mesothelioma (1)
Bronchial Neoplasms (11) · Lung Diseases (11) · Neoplasms by Site (11) · Respiratory Tract Diseases (11) · Respiratory Tract Neoplasms (11) · Thoracic Neoplasms (11) · Neoplasms (8) · Lung Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms, Glandular and Epithelial (6) · Carcinoma (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Gastrointestinal Diseases (3)
Carboplatin (3) · Cisplatin (3) · Etoposide (2) · Paclitaxel (2) · durvalumab (2) · ALT-803 (1) · Azacitidine (1) · Biological Assay (1) · Biological Products (1) · Docetaxel (1) · Eflornithine (1) · Gemcitabine (1) · HhAntag691 (1) · Injections (1) · Interleukin-2 (1)
National Cancer Institute (NCI) (2) · Amgen (1) · Cancer Research UK (1) · Dwight Owen (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Human Genome Sciences Inc., a GSK Company (1) · JS InnoPharm, LLC (1) · NextPoint Therapeutics, Inc. (1) · PACT Pharma, Inc. (1) · University of Maryland, Baltimore (1)
United States (10) · United Kingdom (1)
David S Schrump, M.D. (2) · Dwight H Owen, MD (1) · Fiona Blackhall, Prof (1) · Jhanelle E. Gray, M.D. (1) · Leena Gandhi, MD, PhD (1) · Taofeek Owonikoko, MD, PhD (1)
PMID 35537408, PMID 36356599, PMID 39897044
2019 (1)